Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.

MLA

Nghiemphu, Phioanh Leia, et al. “Imaging as an Early Biomarker to Predict Sensitivity to Everolimus for Progressive NF2-Related Vestibular Schwannoma.” Journal of Neuro-Oncology, vol. 167, no. 2, Apr. 2024, pp. 339–48. EBSCOhost, https://doi.org/10.1007/s11060-024-04596-4.

APA

Nghiemphu, P. L., Vitte, J., Dombi, E., Nguyen, T., Wagle, N., Ishiyama, A., Sepahdari, A. R., Cachia, D., Widemann, B. C., Brackmann, D. E., Doherty, J. K., Kalamarides, M., & Giovannini, M. (2024). Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of Neuro-Oncology, 167(2), 339–348. https://doi.org/10.1007/s11060-024-04596-4

Chicago

Nghiemphu, Phioanh Leia, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R Sepahdari, et al. 2024. “Imaging as an Early Biomarker to Predict Sensitivity to Everolimus for Progressive NF2-Related Vestibular Schwannoma.” Journal of Neuro-Oncology 167 (2): 339–48. doi:10.1007/s11060-024-04596-4.